Corvus Pharmaceuticals (CRVS) Insider Scott Buys $250K of Stock
David Scott Moore purchased 15,000 shares of CRVS on June 11.
Reviewed by automated data checks against the source filing. How we make and check alerts
Moore David Scott bought 21,700 shares of Corvus Pharmaceuticals, Inc. ($CRVS) at an average price of $11.53, worth about $250,201, on June 11, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CRVS is up 2.7% after 1 week, up 26.8% after 1 month and down 17.9% to date (from the $11.60 close on Jun 11, 2026).
CRVS
Corvus Pharmaceuticals, Inc.
Key Points
- David Scott Moore bought 15,000 shares of CRVS on June 11, with the stock trading at $11.93.
- CRVS shares have been actively traded by institutional investors, with BlackRock adding over 1.1 million shares.
- Analysts maintain a positive outlook on CRVS, with Goldman Sachs setting a $40 price target.
Get $CRVS trade alerts by text
We text you when insiders, Congress or big funds trade $CRVS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Corvus Pharmaceuticals, Inc. alert may contain errors. Disclosures
On June 11, 2026, insider David Scott Moore purchased 15,000 shares of CRVS. This transaction was not part of a pre-planned trading program, and the shares were acquired at no cost. The market valued CRVS stock at $11.93 on the same day.
Insider Buying and Selling at Corvus Pharmaceuticals, Inc.
Several insiders, including David Scott Moore, were active on June 11, 2026. Moore acquired 15,000 shares, while Peter Thompson, Richard Van Den Broek, Linda Grais, and Ian Clark each bought the same number of shares. These transactions were not planned in advance, and each insider acquired their shares at no cost.
Other Institutional Activity in CRVS
Institutional investors have shown interest in CRVS. BlackRock, Inc. increased its holdings by over 1.1 million shares, bringing its total to 6,160,422 shares valued at approximately $90.1 million. State Street Corp also boosted its position by 777,769 shares, resulting in 3,565,992 shares worth about $52.2 million. Meanwhile, Price T Rowe Associates dramatically increased its stake by nearly 2.9 million shares, totaling 2,917,300 shares valued at $42.7 million.
Analysts Set New Price Targets
Analysts maintain a favorable view of CRVS, with several firms reiterating or initiating positive ratings. On April 17, 2026, Goldman Sachs initiated coverage with a 'buy' rating and a $40 price target. Oppenheimer reiterated its 'buy' rating with a $33 target on March 13, 2026. Jefferies maintained its 'buy' stance with a $42 target on January 22, 2026. The consensus among analysts is a 'buy', reflecting a positive outlook for the stock.
Bottom Line
The recent insider purchases by David Scott Moore and others suggest confidence in CRVS's prospects. Institutional interest, as evidenced by BlackRock's significant share increase, further underscores this sentiment. Analysts are optimistic, with several firms setting high price targets. As always, it's important to remember that insider and institutional activities are historical data and may not indicate future performance.
Related Filing Alerts
Source: Moore David Scott's Form 4 filing on $CRVS (Jun 11, 2026). Find the original filing: CRVS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts